Introduction
============

Cardiovascular disease (CVD) is the leading cause of death among adults worldwide ([@b14-vhrm-4-1127]), and in Canada it accounts for 37% of total mortality ([@b10-vhrm-4-1127]; [@b5-vhrm-4-1127]). Dyslipidemias, in particular elevated low-density lipoprotein-cholesterol (LDL-C) or decreased high-density lipoprotein cholesterol (HDL-C), are important risk factors for the development of vascular disease and recognized to be major independent risk factors for coronary heart disease (CHD) ([@b3-vhrm-4-1127]; [@b1-vhrm-4-1127]; [@b16-vhrm-4-1127]; [@b23-vhrm-4-1127]). Evidence from several large randomized controlled trials have demonstrated the benefit of treating patients both with and without documented CVD across the spectrum of cholesterol levels with various lipid-lowering medications. A meta-analysis of these trials demonstrated that intervention with hydroxymethyl glutaryl-coenzyme A reductase inhibitors (statins) showed a large and statistically significant reduction in mortality from CHD (19% per mmol/L reduction in LDL-C) and from all-causes (12% per mmol/L reduction in LDL-C) ([@b2-vhrm-4-1127]).

On the basis of this robust cumulative evidence, expert groups have promulgated and regularly updated national guidelines to assist health care practitioners with the treatment of patients with dyslipidemias ([@b15-vhrm-4-1127]; [@b13-vhrm-4-1127]). The latest updates of these guidelines provide a strategy to risk stratify patients according to data adapted from the Framingham study, based on their individual estimated 10-year risk of experiencing a cardiac endpoint such as a nonfatal myocardial infarction or death from CHD ([@b8-vhrm-4-1127]; [@b15-vhrm-4-1127]; [@b13-vhrm-4-1127]). Despite these efforts, numerous practice-pattern analyses indicate that the treatment of patients is suboptimal. Patients are under-diagnosed, under-treated and are not achieving lipoprotein targets ([@b20-vhrm-4-1127]; [@b12-vhrm-4-1127]; [@b18-vhrm-4-1127]; [@b6-vhrm-4-1127]; [@b4-vhrm-4-1127]; [@b22-vhrm-4-1127]).

Lipid and cardiovascular risk reduction clinics (CRRC) have been developed to provide assistance in the management of patients with dyslipidemias. A number of studies have evaluated the effectiveness of these specialty clinics. Compared to management by primary care physicians or specialists in other nonlipid clinics, patients who are managed in CRRC or lipid clinics have lower LDL-C levels and are more likely to achieve their lipid targets ([@b21-vhrm-4-1127]; [@b9-vhrm-4-1127]; [@b25-vhrm-4-1127]; [@b26-vhrm-4-1127]; [@b7-vhrm-4-1127]; [@b11-vhrm-4-1127]; [@b17-vhrm-4-1127]). Additional evidence demonstrates that patients referred to a CRRC were also able to achieve significant improvements in other cardiovascular (CV) risk factors, such as blood pressure and glycemic control ([@b17-vhrm-4-1127]).

While previous studies have evaluated the effectiveness of reducing lipid levels within the clinic itself or in comparison to primary care practices, to our knowledge no study has determined the level of lipid control for patients subsequent to their discharge from these clinics. This is important since there is uncertainty as to whether patients should be discharged, at some point in their care, back to their primary care physician or continued to be followed in the CRRC. Clearly, this has significant resource implications for these clinics and their patients. The purpose of this study was to determine the long-term impact on lipid control among patients who were initially managed in a CRRC and subsequently discharged to primary care follow-up.

Methods
=======

Study design
------------

This was a retrospective cohort study among consecutive patients followed within a single CRRC at the University of Alberta Hospital in Edmonton, Alberta, Canada. The Canadian health care system provides for universal access to essential medical and physician services. Prescription drug coverage is provided provincially for seniors (age ≥65 years) and the indigent; otherwise, third party drug insurance is paid for by individuals and/or their employers. This clinic utilizes a multi-factorial risk reduction model, which targets individualized changes in lifestyle and pharmacologic treatment to decrease patients' risk of developing or worsening CVD. The clinic is staffed ½ to 1 day per week by a dedicated multidisciplinary team of physicians (2 to 3 per clinic day), pharmacists, nurses, and dieticians. Together, the clinic team provides a comprehensive program that consists of a combination of education and counseling (nutrition, smoking cessation, and physical activity), behavioral interventions and pharmacotherapy, individually tailored to each patient to optimally reduce their CV risk profile. In addition to in-person follow-up for patients within the clinic, the CRRC also provides intermittent telephone follow-up for patients when necessary.

The study was reviewed and approved by the Health Research Ethics Board at the University of Alberta.

Patients
--------

Our study group was comprised of consecutive patients referred to the CRRC for either primary or secondary prevention of CVD between January 1991 and January 2001. Patients were identified from clinic records and determined to be eligible for this study if they were: ×18 years of age, had any form of dyslipidemia (elevation of any component of the fasting lipid profile) at the time of referral, attended a minimum of one clinic visit, and had at least one follow-up lipid profile reflecting CRRC management, and had been discharged from the CRRC back to their primary care physician for at least 6 months. Patients were excluded from the study if their primary care physician refused to participate or failed to respond to the investigators' repeated requests for study related data or the primary care physician did not have a follow-up lipid profile for the patient at least 6 months after they were discharged from the CRRC.

Procedures
----------

The primary care or referring physician for each patient fulfilling the eligibility criteria who was discharged from the CRRC was contacted to obtain the results of the most recent lipid profile. Participating physicians' offices were requested to fax a copy of their patients' most recent lipid profile report to the project office. In an attempt to optimize the number of patients included in the study, follow-up letter reminders to nonresponding physicians occurred in accordance to published criteria ([@b19-vhrm-4-1127]).

The medical records of all eligible patients were reviewed. The following data were abstracted: patient demographics (age, sex), complete fasting lipid profiles (total cholesterol \[TC\], LDL-C, HDL-C, triglycerides \[TG\], and TC:HDL-C ratio), and the number and nature of cardiac risk factors. Cardiac risk factors were defined as chart documentation by a physician of the following: hypertension, diabetes mellitus, smoking, previous myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), angina, peripheral arterial disease (PAD) (ie, end-arterectomy or symptoms suggestive of PAD), and cerebral vascular disease (transient ischemic attack or stroke). Additional cardiac risk information was collected, if available, including the presence of electrocardiogram documented left ventricular hypertrophy (LVH), impaired fasting glucose or impaired glucose tolerance, and family history of premature CV disease (history of CAD in a first-degree relative before the age of 55 years in a male or 65 years in a female). Lipid-lowering medications prescribed during CRRC assessment and follow-up were also collected.

Outcome measures and statistical analysis
-----------------------------------------

The primary outcome was the change in patients' lipid levels between the final CRRC visit (discharge) and the most recent lipid levels obtained by the patients' physician at least 6 months after they were discharged from the CRRC (follow-up). The secondary outcome of interest was the change in patients' lipid levels between the initial referral (baseline) and the final visit to the CRRC (discharge). The before and after changes in the lipid parameters (TC, LDL, HDL, TG, and TC:HDL) were compared using generalized least squares approach. This was employed due to missing data and to account for the assumption of unequal variance-covariance over time. The least square means and 95% confidence interval of the differences of means with Tukey-Kramer adjustments for pair-wise comparisons were provided for each interval change in the lipid parameters. The descriptive demographic characteristics of all patients and those patients remaining in the follow-up period after final visit to the CRRC were summarized using means for continuous variables and proportions for categorical variables. In order to evaluate the potential impact of the patients in whom the follow-up lipid profiles post-discharge from the CRRC were not obtained, a second analysis was conducted. The worst-case scenario was used for all patients without follow-up labs and their original baseline lipid values at the time of referral were imputed for the post-discharge follow-up values. Statistical significance was set at a p-value of \<0.05. All statistical analyses were performed using SAS statistical software (version 8.2; SAS Institute Inc. Cary, NC).

Results
=======

[Figure 1](#f1-vhrm-4-1127){ref-type="fig"} summarizes the overall disposition of patients in the study. There were 1,975 patients referred to the CRRC between January 1991 and January 2001. From this population, 1,064 patients (53.9%) fulfilled the study eligibility criteria and were evaluated within the CRRC. The reasons for excluding 911 patients were: age less than 18 years (n = 42), no diagnosis of a dyslipidemia at the time of referral (n = 139), no follow-up lipid profile reflecting the CRRC management (n = 269), not discharged from the CRRC at the time of the study or discharged for less than 6 months (n = 415), deceased (n = 22), and medical record unavailable for review (n = 24). Follow-up fasting lipid profiles were obtained for 411 (38.6%) of the patients who were eligible for the study. Patient demographics for those with and without follow-up lipid profiles are outlined in [Table 1](#t1-vhrm-4-1127){ref-type="table"}.

Changes in lipid levels within the CRRC
---------------------------------------

Overall, the impact of the CRRC management was assessed in 1064 patients (mean age = 51.9 ± 12.4 years; 41.8% female) followed for a median duration of 1.28 years (mean number of clinic visits = 3.6; mean additional follow-up contacts by telephone = 4.1). There were 473 (44.5%) high-risk patients, with a documented history of vascular disease (n = 311) or diabetes and age \>30 years (n = 162); the median CRRC follow-up in this sub-group was 1.57 years (mean number of clinic visits = 4.5; mean additional follow-up telephone contacts = 5.8). The remaining 591 (55.5%) patients were identified to have a mean of 2 cardiovascular risk factors. The distribution of risk factors, documented incidence of specific vascular disease, and other demographics are outlined in [Table 1](#t1-vhrm-4-1127){ref-type="table"}.

The CRRC achieved improvements in all lipid parameters ([Table 2](#t2-vhrm-4-1127){ref-type="table"}). The observed changes between the time of referral and discharge from the CRRC were decreases in LDL-C (19.1%), TC (17.9%), TG (40.3%), and TC:HDL (22.8%), as well as an increase in HDL-C (8.9%), which were all statistically significant (p \< 0.0001). These changes were achieved with a high frequency of lipid-lowering medication use ([Table 3](#t3-vhrm-4-1127){ref-type="table"}). There were a total of 1,593 lipid-lowering medication prescriptions in the 1,064 patients (average of 1.5 medications/patient) used during CRRC follow-up. Statins were the most commonly used class of agents, with 82.7% of patients being prescribed one of these agents while in the CRRC. Fibrates were prescribed in 37.9% of patients, niacin in 13% and a resin in 6.1%. In addition, combination lipid-lowering regimens ([Table 4](#t4-vhrm-4-1127){ref-type="table"}) were utilized with a high frequency in this population, with 19.1% of patients being prescribed combination therapy at some point in time; a two-drug combination regimen was used in 18.6% of patients and 0.5% of patients used three-drug combination therapy. The most frequently prescribed combination regimen consisted of a statin plus a fibrate, which was used in 13.1% of patients.

Post-discharge from the CRRC
----------------------------

To assess the impact of lipid control after patients were discharged from the CRRC, complete follow-up lipid profiles were assessed in 411 patients. The mean age of this group was 52.6 ± 11.5 years; 47.7% were females and 172 (41.8%) were high-risk patients. The median duration between CRRC discharge and the most recent lipid profile was 2.41 years. Compared to the total population evaluated within the CRRC, there were no obvious differences in these patients with regard to the incidence of documented vascular disease, diabetes, or other risk factors for CV disease ([Table 1](#t1-vhrm-4-1127){ref-type="table"}). [Table 5](#t5-vhrm-4-1127){ref-type="table"} outlines differences in fasting lipid profiles between CRRC discharge and the most recent follow-up post-discharge. There were no significant differences observed in LDL-C, TC, or TG. However, there were small, but statistically significant, improvements in HDL-C (+0.03 mmol/L; p \< 0.05) and TC:HDL ratio (−0.20; p \< 0.05) observed in the most recent follow-up lipid profiles of these patients. Analysis of the high-risk sub-group demonstrated no significant change in any of the lipid parameters between discharge from the CRRC and the most recent follow-up.

In the worst-case analysis, the original baseline lipid values at the time of referral were imputed for the 653 patients for whom follow-up labs could not be obtained, and this data was combined with that for the 411 patients with follow-up lipid values. For 414 patients (39%), no reply for follow-up lipid profile results was obtained from the original referring physician (351 patients; 33%) or the referring physician refused to participate in the study (63 patients; 6%). For 239 patients (22.5%), the referring physician replied but was unable to provide the patient's recent lipid profile. Of these, recent lipid values were not available for 156 patients (14.7%) because the physician no longer cared for the patient (died, moved, or switched physicians) and there were 83 patients (7.8%) still under the referring physician's care in whom no recent follow-up lipid screen had been ordered. The 653 patients with no follow-up data were older and had a larger percentage of male patients compared to the group with follow-up data, but otherwise appeared to be similar to those patients for whom follow-up labs were available. The unadjusted worst-case analysis demonstrated a statistically significant worsening of all lipid parameters between CRRC discharge and the most recent follow-up ([Table 6](#t6-vhrm-4-1127){ref-type="table"}). However, when the change in lipid parameters between the baseline (visit I) and the most recent follow-up was assessed in this analysis, the reductions in TC (−0.53 mmo/L), LDL-C (−0.39mmol/L), TG (−0.83 mmol/L), and TC:HDL ratio (−0.67) and the increase in HDL (+0.06 mmol/L) were all statistically significant (p \< 0.05).

Discussion
==========

In an attempt to improve the management of dyslipidemias in patients with CHD or at high-risk for developing future CVD events, specialty clinics have been developed within many institutions. Studies evaluating the effectiveness of these specialty clinics have demonstrated significant improvements in lowering LDL-C levels, achieving lipid targets, and reducing other cardiac risk factors compared to usual care ([@b21-vhrm-4-1127]; [@b9-vhrm-4-1127]; [@b25-vhrm-4-1127]; [@b26-vhrm-4-1127]; [@b7-vhrm-4-1127]; [@b11-vhrm-4-1127]; [@b17-vhrm-4-1127]). While the evidence clearly demonstrates that specialty cardiovascular risk reduction or lipid clinics are very effective in managing patients with dyslipidemias and other risks for CVD, all published evaluations of these practices have focused on the outcomes achieved while the patients are managed within the clinic. The present study demonstrated that the improvements achieved in all lipid parameters during attendance at the CRRC were maintained in both high-risk and moderate-risk patients over a median follow-up of 1.28 years. During this time patients were seen in the clinic for a mean of 3.6 visits and received an additional 4.1 clinic telephone contacts.

The very high frequency of medication use by the CRRC is one probable explanation for the significant change in lipids observed in the patients during clinic follow-up. An average of 1.5 lipid-lowering medications/patient used during CRRC follow-up reflects a high rate of medication change for efficacy or toxicity reasons, as well as the need for combination therapy in many patients (19.1%). In a previous study within our population, we demonstrated that commonly prescribed combination regimens (statin + fibrate and statin + niacin) were safe and effective when patients are well informed about the potential toxicities and judiciously monitored ([@b24-vhrm-4-1127]). Not surprisingly, statins were the class of lipid-lowering agents most commonly prescribed, used in \>82% of our patients. In addition to lipid-lowering therapy medication recommendations and adjustments, the significant changes in the lipid profiles observed in the clinic might also be attributed to the structured, one-to-one education and counseling that patients received with the CRRC multidisciplinary team for dietary modification, alcohol consumption, exercise, and smoking cessation during clinic follow-up.

As the primary outcome, we assessed the effectiveness of the CRRC in managing dyslipidemias in 1,064 patients over a 10-year period, demonstrating statistically significant improvements in all lipid parameters. These improvements were achieved over a median of 2.41 years following last clinic follow-up. We successfully obtained the recent lipid profiles, measured ≥6 months after discharge from the CRRC, from referring primary care physicians for 39% of the eligible patients. The reasons for follow-up lipid profile results not being obtained in the other 653 patients were provided. Interestingly, there were 83 patients (7.8%) still under the referring physician's care in whom no recent follow-up lipid screen had been ordered. The lack of follow-up lipid screening is surprising, since it is standard practice for the clinic physicians to recommend the referring physician continue to assess the patients' lipid profile every 6 to 12 months after discharge from the clinic. However, given the patient volume and busy clinical practices of most primary care physicians, some may have delayed ordering follow-up up lipid panels for longer periods of time because they or their patients had the general impression that the lipid profiles were already optimized.

The worst-case analysis, in which the missing follow-up lipid values for 653 patients were imputed, demonstrated that approximately 50% of the improvement in the lipid parameters was lost between discharge and follow-up for the entire study population of 1064 patients. This observation is not surprising since we imputed the original baseline values for 653 patients (61.4%) in this analysis; however, one could argue that we should have expected to have observed a greater loss in the benefit in the mean lipid levels in this cohort following discharge, consistent with the proportion of patients for whom the baseline lipid values were imputed. This analysis demonstrated that overall change in each lipid parameter between the initial clinic visit and follow-up remained both statistically and clinically significant.

Based on data from a meta-analysis by [@b2-vhrm-4-1127], the 0.97 mmol/L mean reduction in LDL-C that was observed in the 411 patients in whom follow-up lipid profiles were obtained ([Table 5](#t5-vhrm-4-1127){ref-type="table"}) would be expected to result in an 18.4% reduction in CHD mortality and a 11.6% reduction in all-cause mortality after 5 years of treatment; however, based on our worst-case analysis ([Table 6](#t6-vhrm-4-1127){ref-type="table"}), the 0.39 mmol/L would be expected to reduce CHD mortality by 7.4% reduce all-cause mortality 4.7% after 5 years of treatment. Undeniably, these statistically significant changes in lipid parameters should translate into clinically significant improvements in patient outcomes over time.

No attempt was made in this study to determine the percentage of patients who successfully achieved their cholesterol goals given that there were no published guidelines for lipid targets during the earlier years of the clinic and guideline recommendations at various times over the 10-year study period were different. This was a retrospective evaluation; therefore, this study is subject to the same limitations as any retrospective study. However, the CRRC has been consistently staffed by a relatively small number of physicians who followed the same general charting procedures during the study period. In addition, the investigators utilized both inpatient and outpatient clinic charts to obtain the patient data which broadened the source of reliable documentation. We were unable to determine if there were other variables in addition to attending the CRRC, which may have influenced the sustained benefits that were observed in the lipid profiles of follow-up patients. Given the consistency in all lipid parameters between the final in-clinic results and the most recent profiles following CRRC discharge, it seems logical to assume that both patients and referring physicians adhered to the recommendations implemented in the clinic; however, we cannot definitively state that there were not other factors that contributed to this sustained benefit. While it was beyond the scope of this study to determine medication and lifestyle modification adherence among patients, this information would be helpful in determining how much of the observed long-term lipid improvements were the result of the CRRC management efforts. Finally, this study was conducted in a single clinic with its own unique patient referral biases, specific clinic experiences, and multidisciplinary staffing pattern which may potentially limit the generalizability of these findings to other specialty clinic practices. The findings of our study may only be applicable to other multidisciplinary clinics, which utilize a similar multifactorial risk-reduction model.

The results of this study suggest that a formally structured CRRC has a significant positive impact on improving important lipid parameters. These improvements appear to be sustained over the long-term after patients are discharged from the CRRC. This evidence lends support to the belief that patients can be discharged from these clinics once they are optimally managed, without compromising the improvements achieved in their CV risk profile. Given that the goal of specialty lipid clinics is to prevent cardiac events in patients with CHD or at high-risk for developing CVD in the future, discharging patients once they have their CV risks optimally managed will facilitate a greater number of patients being seen and benefiting from the multidisciplinary, structured approach to risk reduction provided by such clinics.
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###### 

Patient demographics

  Parameter                                                                   All patients (n = 1064)   Patients with follow-up (n = 411)   Patients with no follow-up (n = 653)
  --------------------------------------------------------------------------- ------------------------- ----------------------------------- --------------------------------------
  Age (mean ± SD)                                                             51.9 ± 12.4               52.6 ± 11.5                         57.4 ± 13.0
  *Sex*                                                                                                                                     
  Males                                                                       619 (58.2%)               215 (52.3%)                         404 (61.9%)
  Females                                                                     445 (41.8%)               196 (47.7%)                         249 (38.1%)
  *Documented vascular disease*[\*](#tfn1-vhrm-4-1127){ref-type="table-fn"}                                                                 
  Prior myocardial infarction                                                 210 (19.7%)               75 (18.2%)                          135 (20.7%)
  Angina                                                                      175 (16.4%)               62 (15.1%)                          113 (17.3%)
  Percutaneous coronary intervention                                          111 (10.4%)               44 (10.7%)                          67 (10.3%)
  Coronary artery bypass graft surgery                                        118 (11.1%)               43 (10.5%)                          75 (11.5%)
  Transient ischemic attack                                                   31 (2.9%)                 12 (2.9%)                           19 (2.9%)
  Stroke                                                                      32 (3.0%)                 9 (2.2%)                            23 (3.5%)
  Peripheral vascular disease                                                 47 (4.4%)                 11 (2.7%)                           36 (5.5%)
  Diabetes mellitus                                                           162 (15.2%)               63 (15.3%)                          99 (15.2%)
  High risk patients (history of vascular disease or diabetes)                473 (44.4%)               172 (41.8%)                         301 (46.1%)
  *Distribution of risk factors*                                                                                                            
  Hypertension                                                                390 (36.7%)               151 (36.7%)                         239 (36.6%)
  Current smoker                                                              214 (20.1%)               80 (19.5%)                          134 (20.5%)
  Positive family history                                                     642 (60.3%)               251 (61.1%)                         391 (59.9%)
  Left ventricular hypertrophy                                                29 (2.7%)                 5 (1.2%)                            24 (3.7%)
  *Other factors*                                                                                                                           
  Impaired fasting glucose or impaired glucose tolerance                      69 (6.5%)                 27 (6.6%)                           42 (6.4%)
  Solid organ transplant                                                      47 (4.4%)                 8 (1.9%)                            39 (6.0%)
  Number of risk factors identified among nonhigh risk patients (mean)        2                         2                                   2

**Note:** \*not mutually exclusive.

###### 

Change in mean lipid levels in 1,064 patients during CRRC attendance

  Lipid parameter   Visit I -(Baseline)   Final visit (Discharge)   Change         
  ----------------- --------------------- ------------------------- -------------- -------------
                                                                    **Mean (%)**   **p-value**
  TC (mmol/L)       6.99                  5.73                      −1.25 (17.9)   \<0.0001
  LDL-C (mmol/L)    4.25                  3.39                      −0.81 (19.1)   \<0.0001
  HDL-C (mmol/L)    1.12                  1.21                      +0.10 (8.9)    \<0.0001
  TG (mmol/L)       4.49                  2.74                      −1.81 (40.3)   \<0.0001
  TC:HDL            6.44                  5.03                      −1.47(22.8)    \<0.0001

**Notes:** Median duration of follow-up in the CRRC (time interval between Clinic Visit I and Final Visit) = 1.28 years.

**Abbreviation:** CRRC, Cardiovascular Risk Reduction Clinic.

###### 

Frequency of lipid-lowering medications used (at any time) during CRRC attendance

  Medication                                           Frequency (\# of instances used)   \% Patients (n = 1064)
  ---------------------------------- ----------------- ---------------------------------- ------------------------
  HMG-CoA (statin)                                     880                                82.7
                                     Atorvastatin      260                                24.4
                                     Pravastatin       238                                22.4
                                     Simvastatin       236                                22.2
                                     Lovastatin        76                                 7.1
                                     Fluvastatin       45                                 4.2
                                     Cerivastatin      25                                 2.3
  Fibric acid derivative (fibrate)                     508                                37.9
                                     Fenofibrate       386                                26.4
                                     Gemfibrozil       102                                9.6
                                     Bezafibrate       20                                 1.9
  Nicotinic acid (niacin)                              138                                13.0
                                     Regular-release   104                                9.8
                                     Timed-release     34                                 3.2
  Bile acid sequestrants (resin)                       65                                 6.1
                                     Cholestyramine    39                                 3.7
                                     Colestipol        26                                 2.4
  Others (Clofibrate, Salmon Oil)                      2                                  0.2

**Abbreviations:** CRRC, Cardiovascular Risk Reduction Clinic; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA reductase.

###### 

Frequency of various combination regimens used (at any time) during CRRC attendance

  Combination regimen         Frequency (\#of Instances Used)   \% Patients (n = 1064)
  --------------------------- --------------------------------- ------------------------
  Statin + Fibrate            139                               13.1%
  Statin + Niacin             25                                2.4%
  Statin + Resin              22                                2.1%
  Statin + Fish Oil           1                                 0.1%
  Fibrate + Niacin            7                                 0.7%
  Fibrate + Resin             2                                 0.2%
  Niacin + Resin              2                                 0.2%
  Statin + Niacin + Fibrate   3                                 0.3%
  Statin + Niacin + Resin     1                                 0.1%
  Statin + Fibrate + Resin    1                                 0.1%
  TOTAL                       203                               19.1%

**Abbreviation:** CRRC, Cardiovascular Risk Reduction Clinic.

###### 

Change in mean lipid levels in 411 patients following discharge from the CRRC

  Lipid parameter   Visit I-(Baseline)   Final visit (Discharge)   Follow-up[\*](#tfn6-vhrm-4-1127){ref-type="table-fn"}   Mean change (95% CI[†](#tfn7-vhrm-4-1127){ref-type="table-fn"})                                                                     
  ----------------- -------------------- ------------------------- ------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  TC (mmol/L)       7.13                 5.81                      5.77                                                    −1.32[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.59, −1.04)   −1.36[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.64, −1.07)   −0.04 (−0.19, +0.1)
  LDL-C (mmol/L)    4.34                 3.44                      3.37                                                    −0.90[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.07, −0.73)   −0.97[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.14, −0.80)   −0.07 (−0.21, +0.07)
  HDL-C (mmol/L)    1.13                 1.24                      1.27                                                    +0.11[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (+0.08, +0.14)   +0.14[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (+0.11, +0.17)   +0.03[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (+0.01, +0.06)
  TG (mmol/L)       4.84                 2.62                      2.64                                                    −2.22[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−3.11, −1.34)   −2.20[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−3.11, −1.30)   +0.02 (−0.20, +0.24)
  TC:HDL            6.54                 5.05                      4.85                                                    −1.49[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.71, −1.27)   −1.69[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−1.95, −1.42)   −0.20[‡](#tfn8-vhrm-4-1127){ref-type="table-fn"} (−0.39, 0.006)

**Notes:** \*Median duration of follow-up since CRRC discharge = 2.41 years (minimum = 0.5 years).

^†^Tukey-Kramer adjustment.

^‡^p\<0.05.

**Abbreviations:** CRRC, Cardiovascular Risk Reduction Clinic; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides.

###### 

Change in mean lipid levels in patients (n = 1064) following discharge from the CRRC by worst-case analysis

  Lipid parameter   Visit I-(Baseline)   Final visit (Discharge)   Follow-up   Mean[\*\*](#tfn11-vhrm-4-1127){ref-type="table-fn"} change (95% CI[†](#tfn12-vhrm-4-1127){ref-type="table-fn"})   
  ----------------- -------------------- ------------------------- ----------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  TC (mmol/L)       6.98                 5.73                      6.46        −0.53[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (−0.63, −0.43)                                                  +0.72[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (+0.58, +0.86)
  LDL-C (mmol/L)    4.1                  3.38                      3.75        −0.39[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (−0.46, −0.33)                                                  +0.38[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (+0.29, +0.46)
  HDL-C (mmol/L)    1.11                 1.21                      1.17        +0.06[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (+0.04, +0.07)                                                  −0.04[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (−0.06, − 0.02)
  TG (mmol/L)       4.53                 2.73                      3.70        −0.83[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (−1.12, −0.54)                                                  +0.97[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (+0.68, +1.25)
  TC:HDL            6.45                 5.04                      5.79        −0.67[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (−0.77, −0.57)                                                  +0.75[‡](#tfn13-vhrm-4-1127){ref-type="table-fn"} (+0.61, +0.89)

**Notes:** \*411 patients had follow-up information and the follow-up lipid values of the remaining 653 patients were imputed from their initial lipid values (baseline at the time of clinic referral);

\*\*Means are least square means and differences in least square means estimates using generalized least squares approach;

^†^Tukey-Kramer adjustment;

^‡^p × 0.05

**Abbreviations:** CRRC, Cardiovascular Risk Reduction Clinic; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides.
